Characterization of novel anti-IL-26 neutralizing monoclonal antibodies for the treatment of inflammatory diseases including psoriasis
- 18 August 2019
- journal article
- research article
- Published by Taylor & Francis in mAbs
- Vol. 11 (8) , 1428-1442
Abstract
Interleukin (IL)-26, known as a Th17 cytokine, acts on various cell types and has multiple biological functions. Although its precise role still remains to be elucidated, IL-26 is suggested to be associated with the pathology of diverse chronic inflammatory diseases such as psoriasis, inflammatory bowel diseases and rheumatoid arthritis. To develop novel neutralizing anti-human IL-26 monoclonal antibodies (mAbs) for therapeutic use in the clinical setting, we immunized mice with human IL-26 protein. Hybridomas producing anti-IL-26 mAbs were screened for various in vitro functional assays, STAT3 phosphorylation and antibiotic assays. Although the IL-20RA/IL-10RB heterodimer is generally believed to be the IL-26 receptor, our data strongly suggest that both IL-20RA-dependent and -independent pathways are involved in IL-26-mediated stimulation. We also investigated the potential therapeutic effect of anti-IL-26 mAbs in the imiquimod-induced psoriasis-like murine model using human IL-26 transgenic mice. These screening methods enabled us to develop novel neutralizing anti-human IL-26 mAbs. Importantly, administration of IL-26-neutralizing mAb did not have an effect on the antimicrobial activity of IL-26. Taken together, our data strongly suggest that our newly developed anti-human IL-26 mAb is a potential therapeutic agent for the treatment of diverse chronic inflammatory diseases including psoriasis.Keywords
This publication has 44 references indexed in Scilit:
- IL-26 Promotes the Proliferation and Survival of Human Gastric Cancer Cells by Regulating the Balance of STAT1 and STAT3 ActivationPLOS ONE, 2013
- IL-26 Is Overexpressed in Rheumatoid Arthritis and Induces Proinflammatory Cytokine Production and Th17 Cell GenerationPLOS Biology, 2012
- Interleukin-26: An IL-10-related cytokine produced by Th17 cellsCytokine & Growth Factor Reviews, 2010
- Distal Regions of the Human IFNG Locus Direct Cell Type-Specific ExpressionThe Journal of Immunology, 2010
- Angiogenesis drives psoriasis pathogenesisInternational Journal of Experimental Pathology, 2009
- The role of the novel Th17 cytokine IL-26 in intestinal inflammationGut, 2008
- Development, cytokine profile and function of human interleukin 17–producing helper T cellsNature Immunology, 2007
- Comprehensive epigenetic profiling identifies multiple distal regulatory elements directing transcription of the gene encoding interferon-γNature Immunology, 2007
- Pathogenesis and therapy of psoriasisNature, 2007
- The T-cell Lymphokine Interleukin-26 Targets Epithelial Cells through the Interleukin-20 Receptor 1 and Interleukin-10 Receptor 2 ChainsJournal of Biological Chemistry, 2004